Latest / Deep Dive Ortho — Orthopaedic Surgery, AI & Digital Health Podcast. / Pigmented Villonodular Synovitis

Transcript

Pigmented Villonodular Synovitis · Deep Dive Ortho — Orthopaedic Surgery, AI & Digital Health Podcast.

0:00
Welcome to The Deep Dive, the show where we really
0:02
try and unravel complex medical conditions, pulling
0:05
out those crucial insights you need to sharpen
0:08
your clinical acumen and, well, navigate some
0:11
challenging patient presentations. Indeed. Today,
0:13
we're embarking on a, I think, truly immersive
0:16
exploration of a condition that, despite its
0:19
benign classification, consistently presents
0:22
clinicians like yourselves with a formidable
0:24
diagnostic puzzle and, frankly, equally complex
0:27
therapeutic dilemmas. We're talking about pigmented
0:32
villanodular synovitis, PVNS. That's right. For
0:35
you, our mid -senior medical professional listeners,
0:38
getting to grips with the nuances of PVNS isn't
0:40
just about expanding your knowledge base, is
0:42
it? It's really about making a tangible difference
0:45
in patient outcomes, often in cases that have
0:47
perhaps baffled others for a long time. Absolutely.
0:50
So to kick us off, perhaps you could explain
0:52
what is the fundamental nature of PVNS and what
0:55
is it that makes it such a perplexing condition
0:58
for those of us in clinical practice? Well, thank
1:00
you. Pigmented Villinodular Cenovitis, PVNS,
1:04
is fundamentally a rare condition. It's benign,
1:07
yes, but locally very aggressive. It's a proliferative
1:11
disorder specifically affecting the synovium.
1:13
The joint lining. Exactly. the joint lining.
1:16
And it's crucial to understand that whilst it's
1:18
considered a subtype of 10 of synovial giant
1:20
cell tumors, it's not actually a true neoplasm
1:23
in the malignant sense. Right. But, and this
1:26
is the key thing, its behavior can be remarkably
1:28
aggressive locally. It can lead to significant
1:31
and often irreversible joint damage if it's not
1:35
identified and managed appropriately. So how
1:37
does that compare to normal synovium? Well, think
1:39
of the synovium in a healthy joint. It's a remarkably
1:42
thin, quite delicate membrane. Its job is producing
1:45
synovial fluid, that vital lubricant which allows
1:48
our cartilage to glide smoothly, lets our joints
1:51
move without friction. In PDNS, this normally
1:54
delicate lining undergoes dramatic uncontrolled
1:57
proliferation. It thickens up immensely, overgrows
2:00
into a dense mass really, and produces an excessive
2:03
amount of fluid. So you get swelling. Exactly.
2:06
Significant swelling. And this accumulation,
2:09
coupled with the sheer bulk of the proliferating
2:11
tissue, resulting in considerable swelling, chronic
2:14
pain, and ultimately a sort of relentless assault
2:17
on the joint architecture itself. And the long
2:19
-term consequences. The real long -term impact
2:22
for patients is its potential for progressive
2:24
joint destruction. We're talking about direct
2:27
erosion of the articular cartilage, cystic remodeling,
2:31
destruction of the underlying subchondral bone.
2:33
Wow. ultimately profound functional impairment
2:36
and significant morbidity if the condition remains
2:40
untreated. And where do we typically see this?
2:42
Well, PVNS can manifest in virtually any joint,
2:46
technically, but the knee is by far the most
2:48
commonly affected. It accounts for up to 80 %
2:52
of all reported cases. 80 %? That's high. It
2:54
is. But we also frequently encounter it in the
2:57
hip. the ankle, the shoulder, and even the elbow.
3:00
And depending on the joint involved, that often
3:01
poses quite significant diagnostic challenges.
3:04
That immediately highlights the core paradox,
3:06
doesn't it? Yeah. Benign by definition, yet potentially
3:09
devastating in its local impact. It's certainly
3:11
a condition that sounds like it could slip under
3:13
the radar quite easily. It does. OK, let's unpack
3:16
this a bit more. Given its complex nature and
3:20
that destructive potential you've outlined, who
3:22
is most typically affected by PVNS? And just
3:25
how prevalent is it really? That rarity must
3:28
contribute to the diagnostic delay you mentioned.
3:31
You've hit on a critical point there. Its rarity
3:33
is indeed a major factor in the diagnostic puzzle.
3:36
To put it into perspective, population -based
3:39
incidence data, mainly from the U .S., actually,
3:42
suggests it's truly uncommon. We're looking at
3:44
approximately 9 .2 new cases per million people
3:47
diagnosed annually. Per million per year. So
3:50
really not common. Not common at all. This low
3:52
incidence means that for many clinicians, it's
3:54
simply not a condition they encounter frequently.
3:57
So naturally, it often gets overlooked in those
4:00
initial differential diagnoses. Makes sense.
4:02
And the typical patient. In terms of the patient
4:04
profile, PVNS primarily affects young to middle
4:08
-aged adults, typically those between, say, 20
4:12
and 50 years of age. There's a noticeable peak
4:15
incidence observed in patients in their third
4:17
and fourth decades, so specifically between 30
4:20
and 40 years old. Now, whilst they can theoretically
4:24
occur at any age, it is exceedingly rare in pediatric
4:27
populations. And that must cause issues. It does,
4:30
unfortunately. When it does present in children,
4:32
it's often misdiagnosed for extended periods.
4:34
Its presentation can be particularly atypical
4:37
in younger patients, leading to delays in appropriate
4:40
management and potentially more advanced disease
4:43
by the time of diagnosis. Right. What about gender?
4:45
Is there a difference between men and women?
4:47
That's interesting, actually. The data offers
4:49
a slightly mixed picture, which can add to the
4:51
diagnostic ambiguity sometimes. Some large -scale
4:55
epidemiological studies indicate and approximately
4:58
equal incidence in men and women, suggesting
5:00
no significant gender predisposition overall.
5:03
However, other investigations, particularly those
5:07
focusing on specific cohorts or perhaps the different
5:10
forms of the disease, suggest a slight female
5:13
predominance, especially it seems in the localized
5:17
form of PVNS. So maybe a slight leaning towards
5:20
women, particularly for the localized type? Possibly.
5:24
It's a nuance clinicians might keep in mind,
5:26
though it's certainly not a definitive diagnostic
5:29
criterion. Understood. You mentioned diagnostic
5:31
delay earlier. Yes, and perhaps one of the most
5:34
clinically significant epidemiological features
5:36
is its insidious onset. Patients frequently experience
5:40
symptoms for a considerable period, sometimes
5:43
years, before a definitive diagnosis is finally
5:46
made. Years? It can be. The median time from
5:49
the initial onset of symptoms to a confirmed
5:51
diagnosis is often reported to be around 18 months.
5:54
Though it can certainly be longer in some cases.
5:57
This prolonged diagnostic delay is a major contributor
6:00
to the progressive joint damage we often see
6:02
because the condition just continues its destructive
6:05
process unchecked. That really underscores why
6:07
increased awareness is so important, doesn't
6:09
it, for GPs and specialists alike? Absolutely.
6:12
Earlier identification and intervention are key.
6:15
18 months is a significant amount of time for
6:17
a patient to endure unexplained pain and functional
6:20
decline. That insidious onset coupled with its
6:24
rarity. Well, it certainly explains why it's
6:26
such a diagnostic conundrum. It is. Now, here's
6:28
where it gets really interesting for us clinicians.
6:32
What do we currently understand about the underlying
6:34
causes and the pathological processes that actually
6:37
drive this condition? It sounds like there must
6:39
be a specific biological engine. behind this
6:43
unusual overgrowth, something beyond just simple
6:46
proliferation. Indeed. Understanding the underlying
6:49
pathophysiology is absolutely key to appreciating
6:52
both its behavior and actually the rationale
6:55
behind some of the emerging targeted therapies.
6:58
Right. While the precise initiating cause of
7:00
PDNS still largely remains unknown, our understanding
7:03
of its genetic and molecular underpinnings has
7:06
advanced dramatically in recent decades. OK,
7:08
what have we found? The most pivotal discovery,
7:10
the one that's truly transformed our sites into
7:12
PVNS is the identification of specific genetic
7:15
translocations. Translocations. Yes. In the overwhelming
7:18
majority of PVNS cases, we find translocations
7:21
involving chromosome 1P13. Right, 1P13. This
7:24
particular genetic rearrangement leads directly
7:26
to the overexpression of the gene encoding colony
7:29
stimulating factor 1, or CSF1, and importantly,
7:32
its corresponding receptor CSF1R. CSF1 and its
7:36
receptor CSF1R. OK. This CSF1 -CSF1R pathway
7:41
is crucial. When CSF1 is overexpressed, it acts
7:44
as a potent growth factor. It attracts and promotes
7:47
the proliferation of various inflammatory cells,
7:50
particularly macrophages, and their precursors,
7:52
which express the CSF1R on their surface. So
7:55
it draws in these cells? Precisely. And what
7:57
happens then is a fascinating but ultimately
7:59
destructive cascade. This over -expression triggers
8:02
the formation of aberrant cell clusters, essentially
8:04
creating focal areas of soft tissue hyperplasia,
8:07
specifically within the synovial lining cells.
8:09
These cells, driven by the CSF1 signaling, then
8:12
begin to form that characteristic thickened,
8:14
overgrown synovial tissue we observe in PVNS.
8:16
That's the engine, then? That's the main engine,
8:18
yes. Beyond the 1P13 translocation, other associated
8:23
chromosomal abnormalities have also been identified,
8:25
though less commonly. Things like a 5 -key -33
8:28
rearrangement, and even prismes of chromosomes
8:30
7 and 5. These further suggest a complex genetic
8:34
predisposition influencing the disease's development.
8:37
So it's complex genetically. It is. But it's
8:39
this fundamental dysregulation of the CSF1R signaling
8:44
pathway that directly underlies the locally aggressive,
8:47
albeit technically benign nature of the disease,
8:50
it's what drives the uncontrolled synovial thickening
8:53
and overgrowth. And what does that look like
8:54
under the microscope when you get a biopsy? Ah,
8:56
yes. When we examine biopsy samples, the histological
9:00
hallmarks are indeed quite distinctive. They
9:02
tell a compelling story of the disease's activity.
9:04
Such as? Microscopically, we observe a proliferation
9:07
of rare, polyhedral synovial -like cells. These
9:11
are the main cellular component of the overgrown
9:13
synovium. Crucially, there are abundant multi
9:16
-nucleated giant cells, which are essentially
9:19
fused macrophages. Now, these giant cells aren't
9:22
specific only to PVNS, but seeing lots of them
9:25
is a strong indicator of an active inflammatory
9:28
or proliferative process. Perhaps the most pathognomonic
9:31
feature, though, is the extensive hemocytarin
9:33
deposition. Hemocytarin, iron deposits. Exactly.
9:37
Hemocytarin is an iron storage complex. And these
9:40
hemocytarin -laden macrophages, often described
9:42
as pigmented foam cells, are what impart the
9:45
characteristic brown, reddish, or sometimes even
9:48
blackish coloration to the affected tissue. Ah,
9:50
the pigmented part of the name. Precisely. This
9:53
pigmentation is a direct visual indicator of
9:56
recurrent, often subclinical, bleeding into the
9:59
joint space. That's a hallmark of PVNS due to
10:02
the fragility and high vascularity of the abnormal
10:04
synovium. Makes sense. What else do you see?
10:06
We also consistently see mononuclear stromal
10:09
cells. These are actually thought to be the neoplastic
10:12
cell population responsible for the CSF1 overexpression.
10:17
The tissue typically forms highly vascular villi,
10:21
sort of frond -like projections lined with plump,
10:23
hyperplastic synovial cells. And frequently,
10:27
common mitotic figures are observed, which confirms
10:29
active cellular proliferation is occurring. Like
10:34
arthritis? Well, there's an intriguing hypothesis
10:36
regarding an inflammatory component, yes. It
10:39
draws some parallels with other chronic arthritic
10:41
conditions, although it's certainly distinct
10:43
from classical inflammatory arthropathies. Some
10:46
studies have explored a potential link between
10:47
prior joint injuries and the onset of PVNS. Trauma?
10:51
Yes, suggesting that trauma might act as a trigger
10:53
or perhaps a predisposing factor in genetically
10:56
susceptible individuals. However, it's important
10:59
for us to note that this correlation hasn't been
11:01
consistently or definitively proven across all
11:03
investigations. Many patients have absolutely
11:06
no history of significant trauma. So maybe a
11:08
link, but not definite. Exactly. Whilst an association
11:12
is often reported in patient histories, a direct
11:15
causative link remains largely unconfirmed. That's
11:19
a profound explanation though, connecting the
11:21
macroscopic presentation directly to that underlying
11:24
genetic and cellular dysregulation. It's really
11:27
clear that understanding this molecular engine
11:29
of PVNS is vital, especially for developing targeted
11:33
therapies. Absolutely. Now, you mentioned the
11:35
local aggression, but it's not all uniform, is
11:37
it? Can you delineate the critical differences
11:40
between localized and diffuse PVNS? As I understand
11:44
it, this distinction isn't just academic. It
11:46
has pretty profound implications for both prognosis
11:49
and the treatment strategies we choose. You're
11:51
absolutely right. The distinction between localized
11:53
and diffuse forms of PDNS is not merely a classification.
11:57
It's a fundamental determinant of clinical behavior,
12:00
prognosis, and most importantly, our therapeutic
12:03
approach. This classification guides virtually
12:05
every decision we make in patient management.
12:08
Okay, so let's start with localized. Right. Localized
12:10
PVNS. This is also frequently referred to as
12:13
the nodular or sometimes the classic form. As
12:16
the name suggests, this variant is characterized
12:18
by a more confined proliferation. Contained.
12:21
Exactly. The tumor typically involves specific
12:23
tendons supporting the joint or it manifests
12:26
as a well -circumscribed, often solitary nodule
12:30
within just one area of the joint capsule or
12:32
synovial lining. How might you feel? On physical
12:35
examination, it can sometimes present as a palpable,
12:38
firm nodule. It might appear skin -colored or
12:41
perhaps slightly brownish. The most common site
12:44
for localized PVNS, particularly within the knee,
12:47
is the anterior compartment, specifically affecting
12:50
the infrapatellar fat pad. The fat pad below
12:53
the kneecap? Precisely. Up to 80 % of localized
12:56
knee cases originate there. which makes sense
12:58
clinically, as the fat pad is a common site for
13:00
synovial proliferation anyway. And symptoms?
13:02
From a patient's perspective, localized PDNS
13:04
is often slow growing and, quite surprisingly,
13:07
may be relatively painless in its early stages.
13:09
Really? Painless? Relatively, yes. However, as
13:13
it grows, it can certainly cause mechanical symptoms
13:16
due to impingement within the joint. things like
13:18
locking, catching, or maybe giving away sensations,
13:21
particularly during specific movements. The key
13:24
clinical takeaway here is its well -defined nature.
13:27
And prognosis. Prognostically, localized PVNS
13:30
generally responds very well to surgical intervention.
13:33
After a complete excision, which is typically
13:36
done via arthroscopic synovectomy. The recurrence
13:39
rate is commendably low, usually around 8%. 8%,
13:42
that's pretty good. It is, which makes it a much
13:44
more manageable form of the disease. Okay, so
13:47
that's localized. What about diffuse? No, in
13:49
stark contrast, we have diffuse PVNS. This form
13:53
is significantly more widespread and, frankly,
13:56
more aggressive. How so? It involves an entire
13:59
joint with extensive, often global thickening
14:02
of the joint lining. A critical characteristic
14:04
is its frequent tendency for extraarticular extension.
14:08
Spreading outside the joint. Exactly. This means
14:10
the disease isn't confined to the joint capsule.
14:13
It can extend significantly beyond infiltrating
14:16
surrounding soft tissues, musculature, even neurovascular
14:19
structures. For example, in the knee, you might
14:21
see extensive posterior extension outside the
14:24
joint capsule, which makes surgical removal far
14:26
more challenging. Right. On imaging, diffuse
14:30
PVNS is typically ill -defined or poorly circumscribed,
14:33
reflecting its infiltrative nature. And clinically?
14:36
Clinically, its behavior is considerably more
14:38
aggressive than the localized form. Patients
14:41
with diffuse PVNS invariably experience more
14:43
severe, persistent pain and profound joint dysfunction.
14:48
It leads to a much greater impact on their quality
14:50
of life. This widespread and infiltrative nature
14:53
makes it inherently more difficult to treat effectively.
14:56
Any specific signs? A frequent presentation and
14:59
indeed a diagnostic hallmark of diffused PVNS
15:01
is its association with long -standing hemorrhagic
15:04
joint diffusions. Bleeding into the joint? Yes.
15:07
Recurrent, often spontaneous. Bleeding into the
15:11
joint space without a preceding traumatic event.
15:14
Patients commonly present with painful masses.
15:16
a markedly decreased range of motion due to the
15:19
synovial thickening and the effusion and diffuse
15:21
tenderness along the joint line. Recurrent atraumatic
15:25
hemorrhothrosis is therefore a strong red flag
15:27
for diffuse PVNS. And the prognosis here? Much
15:30
worse, I imagine. Considerably less favorable,
15:32
yes. Given its more aggressive nature and diffuse
15:35
involvement, despite a therosurgical synovectomy,
15:38
the recurrence rate is significantly higher,
15:40
ranging from approximately 30 % up to 50%. 30
15:43
to 50 % recurrence. That's high. It poses a substantial
15:47
challenge for long -term management and often
15:49
necessitates multimodal or repeated interventions.
15:52
This clear distinction is absolutely tear them
15:54
out for guiding our diagnostic investigations
15:56
and, of course, our subsequent treatment algorithms.
15:58
That's a remarkably clear delineation, and it
16:01
certainly drives home why accurate classification
16:03
is so pivotal. With such varying presentations,
16:07
though, and that insidious onset you've mentioned,
16:10
how does a clinician typically encounter a patient
16:12
with PVNS? What does that first presentation
16:15
often look like? Well, they usually present with
16:18
joint pain. Just pain? Often, yes. Insidious
16:21
onset of joint pain. It can be quite variable
16:24
from a mild sort of nagging discomfort to quite
16:27
severe, poorly localized pain. This is often
16:31
accompanied by a sense of stiffness, particularly
16:33
after periods of rest and noticeable swelling
16:36
in the affected joint. And the bleeding. As we
16:38
discussed, a crucial red flag, especially for
16:40
the diffuse form, is that recurrent atraumatic
16:43
hemarthrosis. Spontaneous bleeding into the joint
16:46
without any clear injury. Patients often describe
16:49
the joint as filling up with blood. What about
16:51
function? Functionally, patients may experience
16:54
a progressive decrease in their range of motion.
16:56
They might notice a palpable mass or a sort of
16:59
fullness around the joint. And they frequently
17:01
complain of mechanical symptoms, locking, catching,
17:04
a sensation of the joint giving way under weight
17:07
bearing. Leading to limping. In more advanced
17:09
cases, yes. It can manifest as a noticeable limp
17:13
or just general difficulty with activities requiring
17:16
use of the affected limb. And the trauma link.
17:18
It's interesting, as I mentioned, about 50 %
17:21
of patients might report a history of prior trauma
17:24
to the affected joint. But the precise correlation
17:27
remains inconsistent, so it shouldn't be relied
17:30
upon as a primary diagnostic indicator. Right.
17:33
It sounds like it could mimic a lot of things.
17:35
Absolutely. The sheer diagnostic challenge here
17:37
cannot be overstated. Because of its slow, progressive
17:41
nature and these non -specific symptoms, patients
17:44
frequently undergo extensive workups for a whole
17:47
myriad of other conditions first. Like what?
17:50
Oh, inflammatory arthrotides like rheumatoid
17:52
arthritis, mechanical issues like displaced meniscal
17:55
tears, infections like septic arthritis, even
17:57
other benign masses such as ganglion cysts, schwannomas,
18:01
or hemangiomas. PVNS is often way down the list
18:04
initially. Until other things are ruled out?
18:07
Often, yes. And what would you find on examination?
18:09
During the physical examination, general inspection
18:12
might reveal joint effusion, indicating fluid
18:15
accumulation, sometimes erythema, maybe if there's
18:18
an inflammatory component or acute bleeding.
18:21
Palpation of the joint often elicits tenderness
18:23
along the joint line, and you might feel a palpable
18:26
mass or just a diffuse, boggy swelling. Limited
18:30
range of motion, both active and passive, is
18:32
a common and often quite profound finding. OK,
18:35
so history and examination give clues. What's
18:39
the comprehensive diagnostic pathway we should
18:41
be pursuing, then, to actually nail the diagnosis,
18:44
especially given that mimicry problem? Right.
18:46
For the diagnostic tools, we employ a multimodality
18:49
approach. Imaging plays a pivotal role here.
18:51
Starting with x -rays. Usually, yes. X -rays
18:54
are typically the initial radiographic studies.
18:56
Now, they might appear normal in early PVNS or
18:59
in the localized forms, but they are essential
19:01
for ruling out other pathologies and can provide
19:04
clues in more What sort of clues? Characteristic
19:07
findings, when they're present, include soft
19:10
tissue swelling and specific bone changes, cystic
19:13
erosions, often with sclerotic margins, on both
19:16
sides of the joint, sometimes called notching
19:18
or pressure erosion, or you might see frank bone
19:21
destruction, sort of punched out lesions caused
19:24
by the direct pressure and erosive activity of
19:26
the proliferating tumor. But x -rays aren't definitive.
19:29
No, definitely not. Magnetic Resonance Imaging,
19:32
MRI, is unequivocally the most sensitive and
19:35
indeed the gold standard imaging study for diagnosing
19:38
PVNS. Why MRI? It provides unparalleled delineation
19:42
of both the intraarticular, so within the joint,
19:44
and any extraarticular disease extension. It
19:47
shows you exactly where it is and how far it's
19:49
spread. What are the key findings on MRI? Key
19:51
findings include significant joint effusion,
19:53
obviously, and that characteristic synovial expansion.
19:56
But the critical MRI signature, the real giveaway,
20:00
relates to the hemocytorin deposits. The iron,
20:02
again. Exactly. These iron deposits appear as
20:05
low signal intensity on both T1 and T2 weighted
20:07
images. And crucially, they produce a distinctive
20:10
blooming artifact on gradient echo sequences.
20:13
Blooming artifact? Yes, it's caused by the paramagnetic
20:16
effect of the iron. It makes the dark areas appear
20:19
much larger than they actually are on those specific
20:21
sequences. This blooming artifact is highly suggestive,
20:25
if not pythognomonic, of PVNS. It's a visual
20:28
confirmation of that recurrent bleeding within
20:31
the synovium. Very characteristic, then, any
20:33
role for CT. Computed tomography, CT scans, are
20:37
less sensitive for the soft tissue detail compared
20:40
to MRI, but they are particularly useful for
20:42
meticulously evaluating the extent of any cystic
20:45
bone loss and osseous erosions. It gives excellent
20:48
bone detail, better than MRI in that regard.
20:50
What about analyzing the joint fluid, arthrocentesis?
20:54
Yes, arthrocentesis, aspirating the joint fluid,
20:57
is indicated for patients presenting with recurrent
20:59
hemathrosis. Analysis of the aspirated fluid
21:02
typically reveals a grossly bloody effusion.
21:04
It might appear dark brown or even blackish due
21:06
to the breakdown products of hemoglobin over
21:08
time. And the final confirmation. The definitive
21:10
diagnosis is typically achieved through diagnostic
21:12
arthroscopy combined with synovial biopsy. Looking
21:15
inside the joint. Exactly. Arthroscopy allows
21:18
for direct visualization. The clinician will
21:21
typically observe the characteristic brownish
21:23
or reddish inflamed synovium, often with its
21:26
distinctive frond -like papillary projections
21:29
or villi. And then you take a piece. Precisely.
21:33
A synovial biopsy taken during the procedure
21:35
is then crucial for microscopic confirmation.
21:38
Histopathological examination reveals those pathognomonic,
21:42
hemocytarin -stained, multinucleated giant cells,
21:45
along with the pigmented foam cells, the mononuclear
21:48
stromal cells, and evidence of active cellular
21:50
proliferation with those mitotic figures we talked
21:53
about. So biopsy confirms it. Any blood tests?
21:56
It's worth noting that routine laboratory tests,
21:58
things like C -reactive protein, CRP, and erythrocyte
22:01
sedimentation rate, ESR, which are markers of
22:04
systemic inflammation, are often completely normal
22:06
in PVNS patients, despite the visible soft tissue
22:09
swelling and the local inflammatory processes
22:12
happening in the joint. So normal inflammatory
22:13
markers can be misleading. They can, unfortunately.
22:16
It can contribute to the delayed diagnosis by
22:19
steering clinicians away from inflammatory causes
22:21
when these markers are within normal limits.
22:23
That comprehensive diagnostic pathway truly underscores
22:26
the complexity. Okay, so once we've navigated
22:29
that labyrinth and finally confirmed a diagnosis,
22:32
what are the established and indeed the emerging
22:34
strategies for managing PVNS, especially given
22:37
its relentless tendency for local aggression
22:39
and that high recurrence rate? It sounds like
22:42
a multi -pronged approach is often necessary.
22:45
You're absolutely right. A multimodal approach
22:47
is essential because PB &S is fundamentally a
22:51
locally destructive process. It actively invades
22:53
and destroys healthy bone and cartilage and can
22:56
grow to a significant size. Therefore, conservative
22:59
management alone is generally ineffective and
23:01
not recommended. So surgery is key. The cornerstone
23:04
of treatment primarily involves surgical intervention,
23:07
yes, to meticulously remove the tumor and the
23:10
affected joint lining. The overarching goal is
23:12
to achieve a maximal, if not complete, marginal
23:15
excision of the diseased tissue. Okay. Tell us
23:18
about the surgical procedures. Right. Surgical
23:20
procedures remain the gold standard. For synovectomy,
23:23
which is removal of the synovium, we differentiate
23:25
based on the extent of the disease. Localized
23:27
versus diffuse again. Exactly. Partial synovectomy
23:31
is typically reserved for localized PV and S.
23:33
This can often be performed arthroscopically.
23:36
particularly for well -defined lesions in accessible
23:39
areas like the anterior knee. Arthroscopic approaches
23:42
offer significant advantages for the patient.
23:45
Such as? Improved functional outcomes, better
23:48
preservation of joint range of motion, and a
23:50
much quicker recovery time compared to open surgery.
23:53
Makes sense. And for diffuse? Well, for grossly
23:57
symptomatic and painful diffused PD &S, a total
24:00
synovectomy is indicated. The AIN here is the
24:03
most complete possible removal of the entire
24:05
joint lining. That sounds much more extensive.
24:08
It often necessitates a fully open surgical approach,
24:11
especially for extensive diffuse disease that
24:13
involves both the front and back of the knee,
24:15
for instance, to ensure a thorough excision of
24:18
all affected tissue. In some complex cases, a
24:21
combined approach might be employed perhaps open
24:23
for the posterior knee, arthroscopic for the
24:26
anterior, which can help to decrease the overall
24:28
surgical invasiveness and potentially aid in
24:30
patient recovery. What if a tendon is damaged?
24:33
Ah, yes. If localized PVNS has caused damage
24:36
to an adjacent tendon, for example, surgical
24:38
repair would be undertaken concurrently during
24:41
the tumor excision. And what if the joint is
24:42
already severely damaged? Yes. For patients presenting
24:45
with advanced disease and extensive joint destruction,
24:48
more radical options become necessary. Like joint
24:51
replacement? Total joint arthroplasty replacement,
24:53
yes. A total knee, hip, or shoulder replacement
24:56
may be required to relieve intractable pain and
24:59
significantly improve function. However, it's
25:02
critical for clinicians and surgeons to be aware
25:05
that these procedures in PVNS patients are associated
25:08
with higher rates of post -operative stiffness,
25:11
heterotopic ossification, and even infection
25:14
compared to standard indications like osteoarthritis.
25:17
So higher risks. Definitely requires meticulous
25:20
preoperative planning and post -operative care.
25:22
Any other options for advanced disease? In severe
25:25
end -stage cases, particularly involving joints
25:27
like the ankle and arthritis or joint fusion,
25:30
might be the only viable option to achieve pain
25:32
relief and stability, albeit at the cost of mobility,
25:35
of course. Okay, so surgery is central. What
25:37
about other treatments? Radiation. Yes, beyond
25:40
surgery, radiation therapy plays a crucial adjuvant
25:43
role. particularly for widespread diffuse PVNS
25:46
or in cases where surgical resection has been
25:49
incomplete or unsuccessful. How does it help?
25:51
Radiation can effectively shrink residual tumor
25:53
burden and significantly reduce the likelihood
25:56
of recurrence. What kind of radiation? Historically,
25:59
external beam radiation was widely used. Typical
26:02
doses were around 30, 35 gray and 15 fractions,
26:06
or perhaps up to 50 gray and 25 fractions. Whilst
26:09
effective, this approach carried potential complications.
26:12
Skin necrosis, joint fibrosis, and in rare instances,
26:16
radiation -induced sarcoma years later. Are there
26:18
newer methods? Yes, a newer, often preferred
26:21
method is intraarticular radiation synovectomy.
26:24
This involves injecting a radioactive colloid
26:26
directly into the joint space. It offers more
26:28
localized treatment and generally fewer systemic
26:30
side effects. And does combining surgery and
26:32
radiation help? Crucially, yes. Contemporary
26:36
evidence clearly demonstrates that when radiation
26:38
therapy is combined with a total surgical synovectomy,
26:41
It significantly reduces the recurrence rate
26:44
of diffuse PDNS. It can bring it down to a more
26:47
manageable range of approximately 10 -20%. 10
26:50
-20%, down from 30 -50, that's a big difference.
26:53
It is. This combination therapy has become a
26:56
standard of care for extensive or recurrent disease.
26:59
Any caveats? Children? Yes, a very important
27:02
point. It's important to underscore that radiation
27:04
is generally avoided in pediatric patients. This
27:07
is due to the significant potential for growth
27:09
plate damage, limb length discrepancies, and
27:12
other serious long -term medical issues associated
27:14
with radiation exposure and developing tissues.
27:17
Right. Now, what about drug therapies? You mentioned
27:19
targeted treatments earlier. Yes. Perhaps one
27:21
of the most exciting and rapidly advancing areas
27:23
is in emerging drug therapies, specifically molecular
27:27
therapeutics. These treatments represent a real
27:29
paradigm shift, moving towards medications that
27:32
specifically target those identified molecular
27:34
drivers of PVNS, particularly the CSF1R protein
27:38
we discussed earlier. The receptor pathway. Exactly.
27:41
Pexadart NIV is a leading example here. It was
27:43
approved by the FDA back in August 2019. It's
27:47
an oral CSF1R inhibitor indicated for adult patients
27:50
with symptomatic tenosynovial giant cell tumor,
27:53
which includes PDNS that's associated with severe
27:56
morbidity or functional limitations and is not
27:59
amenable to improvement with surgery. How effective
28:02
is it? In clinical trials, this oral medication
28:04
typically taken once daily for 24 weeks, has
28:07
demonstrated significant improvement in the PVNS
28:10
disease burden in approximately 40 % of patients.
28:13
It leads to substantial tumor shrinkage and symptom
28:15
alleviation. It's really been a game changer
28:17
for those with extensive surgically complex or
28:21
recurrent disease. 40 % response is significant.
28:23
Are there others in development? Yes. Other promising
28:26
agents are also under investigation. Imakazumab
28:29
is a monoclonal antibody that directly targets
28:31
CSF1R, effectively blocking the signaling pathway.
28:36
PLX3397 is another oral tyrosine kinase inhibitor
28:39
that, similar to Pixadertinib, also inhibits
28:43
CSF1R. Both of these agents have shown objective
28:46
clinical responses in early phase trials, further
28:48
underscoring the validity of targeting the CSF1
28:51
pathway. And combination therapies. Current research
28:53
is also vigorously exploring combination therapies.
28:56
For instance, combining CSF1R inhibitors with
28:59
other targeted agents, perhaps anti -PD -L1 immunotherapy,
29:03
or PA3 -carodact pathway inhibitors like LY294002
29:07
hold significant promise. Why combine them? The
29:10
rationale here is to potentially enhance response
29:12
rates, maybe overcome resistance mechanisms that
29:14
might develop, and improve the durability of
29:16
the treatment. Ultimately, the aim is to further
29:19
improve long -term outcomes and potentially reduce
29:21
the need for repeat surgeries or the progression
29:23
to end -stage joint destruction. This multimodal
29:25
and increasingly targeted approach is truly defining
29:28
the contemporary management of PVNS. It's clear
29:30
that the treatment landscape for PVNS is evolving
29:33
incredibly rapidly, offering a much more diverse
29:36
arsenal than ever before. It's quite hopeful.
29:39
It is. But beyond the immediate intervention,
29:41
whatever it may be, What does the recovery process
29:45
typically look like for a patient who has undergone
29:47
these treatments? And crucially, what are the
29:50
potential pitfalls and complications that we
29:52
as clinicians, and indeed our patients, need
29:55
to be acutely aware of, particularly that notorious
29:58
issue of recurrence? Recovery from PVNS treatment,
30:02
especially surgical intervention, is definitely
30:04
a journey. It requires significant patient commitment
30:07
and meticulous clinical oversight. And yes, vigilance
30:11
for potential complications is key. Rehabilitation
30:14
is absolutely paramount post -surgery. Physical
30:16
therapy. Exactly. To ensure patients regain as
30:19
much strength and range of motion as possible.
30:21
That directly correlates with their long -term
30:23
functional outcome. Does it differ based on the
30:25
type of surgery? Yes, significantly. For those
30:29
undergoing arthroscopic surgery, typically for
30:32
localized PD &S, the recovery is generally quicker
30:35
and less arduous. It usually requires a focused,
30:39
shorter course of physical therapy. This often
30:41
allows for a relatively swift return to normal
30:44
daily activities. And open surgery. However,
30:47
open surgical procedures, particularly those
30:50
extensive total synovectomies for diffuse PVNS,
30:53
are far more invasive. These carry a significantly
30:56
increased risk of post -operative stiffness and
30:59
scar tissue formation. Meaning longer rehab.
31:02
Yes. Necessitating a much more regimented and
31:04
prolonged physical therapy program, often spanning
31:07
several months, to really optimize joint mobility
31:10
and overall function. Okay. Now about those complications.
31:13
Recurrence is the big one. It is. The most frequent
31:15
and indeed the most challenging complication
31:17
is recurrence. While localized PVNS rarely recurs
31:21
after complete surgical excision, the diffuse
31:23
form, as we've said, has a notoriously high recurrence
31:26
rate. Even after apparently complete surgery?
31:28
Yes. Despite what might be considered a complete
31:30
synovectomy, recurrence rates can range from
31:32
10 % to as high as 50%. Why so high? It's often
31:36
attributed to the inherent difficulty in achieving
31:38
a truly complete excision, simply due to the
31:41
infiltrative nature of diffused disease. Microscopic
31:45
remnants of the abnormal synovium can persist
31:47
and lead to subsequent regrowth. And how do we
31:50
mitigate that? As we touched upon, one of the
31:52
most effective strategies is combining surgery
31:55
with adjuvant external beam radiation therapy.
31:58
That can significantly reduce recurrence rates
32:00
down to that more manageable 10 -20 % range for
32:04
diffuse PVNS. Right. What other complications
32:06
should we be aware of? Beyond recurrence, several
32:09
other complications can arise. If PVNS is left
32:12
untreated, or if it progresses despite therapy,
32:15
it inevitably leads to moderate to severe joint
32:17
deformity, progressive degenerative articular
32:20
changes, and ultimately debilitating osteoarthritis.
32:23
Leading to fusion or replacement anyway. Exactly.
32:26
In the most severe and intractable cases, the
32:29
relentless cortical bone destruction and joint
32:31
damage may necessitate more extreme interventions
32:33
like arthrodesis or, in exceptionally rare and
32:36
desperate circumstances, even amputation of the
32:39
affected limb. Gosh, and risks from the treatments
32:41
themselves. Yes, there are specific treatment
32:44
-related risks that we must carefully consider
32:46
and discuss with patients. For patients receiving
32:49
Pexadartinib, the primary and most serious risk
32:52
is hepatic toxicity. Liver problems. Oh, serious.
32:56
It can range from transient elevation of liver
32:58
enzymes to severe and potentially fatal liver
33:00
injury. This necessitates close and vigilant
33:03
monitoring of liver function tests, specifically
33:06
AST and ALT, throughout the treatment course.
33:09
Any other side effects of pexadortinib? Hair
33:11
depigmentation is another commonly noted, though
33:14
obviously less serious, side effect. Okay. And
33:16
surgical risks. Surgical approaches also carry
33:19
their own set of risks, of course. Open surgeries
33:21
by their nature are associated with longer hospital
33:24
stays, increased post -operative pain, and more
33:27
prolonged rehabilitation periods. For instance,
33:30
extensive posterior approaches to the knee, while
33:33
sometimes unavoidable for diffuse disease, place
33:35
critical neurovascular structures like the popliteal
33:38
artery and nerve at risk. And arthroscopy, less
33:40
risky. Less invasive, yes, but it demands considerable
33:44
technical expertise. and it may be less effective
33:47
for very large masses or those with significant
33:50
local tissue invasion. Making a truly complete
33:53
excision challenging arthroscopically can potentially
33:56
lead to higher recurrence rates if not performed
33:59
meticulously. And radiation risks. Radiation
34:01
therapy, while effective in reducing recurrence,
34:04
carries risks including local skin changes, fibrosis,
34:07
and in extremely rare cases, the induction of
34:10
a secondary radiation -induced sarcoma many years
34:12
post -treatment. Finally, what about spread?
34:15
Metastasis. Right. While PVNS is overwhelmingly
34:18
a localized disease, it is important to acknowledge
34:20
that there have been exceedingly rare documented
34:23
instances of metastasis to distant sites, lungs,
34:26
muscles, regional lymph nodes. But very rare.
34:29
Exceptionally rare. And it's absolutely crucial
34:31
to emphasize that this is far more commonly associated
34:34
with the truly malignant forms of tenosynovial
34:36
giant cell tumors rather than the typically benign,
34:39
albeit locally aggressive, PVNS we're mostly
34:41
discussing. That distinction is very important
34:44
for patient counseling and prognostication. That's
34:46
a comprehensive and frankly quite sobering overview
34:49
of the challenges in recovery and the potential
34:52
complications. It truly reinforces the need for
34:55
ongoing vigilance and careful management. It
34:57
does. Despite these hurdles. What's the long
35:00
-term outlook generally for patients diagnosed
35:02
with PVNS? And perhaps more optimistically, what
35:05
exciting avenues are researchers currently exploring
35:08
to improve patient care and those long -term
35:10
outcomes? Well, the prognosis for PVNS from a
35:13
life expectancy perspective is generally good.
35:16
It's rarely a fatal disease. That's reassuring.
35:19
It is. However, its primary impact is really
35:22
on the patient's quality of life. It's a condition
35:24
that relentlessly erodes joint function. leading
35:27
to chronic pain, reduced mobility, and considerable
35:30
difficulty with daily activities. So function
35:32
is the main issue? Primarily, yes. The long -term
35:34
outlook for functional preservation ultimately
35:36
hinges on several intertwined factors. The initial
35:39
size and anatomical location of the tumor, the
35:42
extent of its spread localized versus diffuse,
35:44
and most critically, the timeliness and efficacy
35:47
of the chosen treatment. And recurrence plays
35:49
a big role. Absolutely. While surgical cure is
35:52
certainly achievable, particularly for the localized
35:55
form, the persistent high recurrence rate of
35:58
diffuse PVNS means that accelerated degenerative
36:01
changes within the joint are a common long -term
36:04
reality. This often leads to the eventual need
36:07
for a total joint arthroplasty to manage pain
36:09
and restore some semblance of function. And you
36:12
mentioned replacements in PVNS patients have
36:14
unique issues. Yes. It's vital for orthopedic
36:17
surgeons to be aware that total knee arthroplasty,
36:19
for example, when performed in patients with
36:21
a history of PVNS, is indeed associated with
36:24
its own unique set of complication rates, often
36:26
higher rates of stiffness, infection, and even
36:28
recurrence of PVNS around the prosthesis, compared
36:31
to standard osteoarthritis indications. This
36:34
necessitates specific surgical considerations
36:36
and thorough patient counseling. Right. Looking
36:38
to the future, then. What's happening in research?
36:40
The landscape of PVNS research is incredibly
36:43
vibrant and advancing at a rapid pace. This is
36:45
largely driven by the identification of those
36:47
key genetic and molecular factors, particularly
36:50
the CSF1R pathway. Beyond CSF1R. Researchers
36:54
are actively investigating novel molecular targets
36:57
beyond just CSF1R. For instance, factors like
37:02
PLIN, PPP -2A, and Tyro -BP have been identified
37:06
as potentially playing roles in the disease's
37:08
pathogenesis. Understanding their specific involvement
37:10
could unlock entirely new diagnostic biomarkers
37:14
and, more importantly, innovative therapeutic
37:16
strategies targeting different pathways. That
37:18
could potentially improve patient outcomes even
37:20
further. And improving current therapies. Yes.
37:23
A significant area of focus is also on optimizing
37:26
existing therapies. There are extensive ongoing
37:28
efforts to refine of targeted molecular therapies,
37:31
like Pexamartinib and other CSF1R inhibitors.
37:35
This includes exploring optimal dosing regimens,
37:37
duration of treatment, and identifying patient
37:39
subgroups who might respond best, or conversely
37:42
those likely to develop resistance. Furthermore,
37:45
there's considerable research into various combination
37:47
approaches. We talked about that. Exactly. combining
37:50
anti -PD -L1 immunotherapy with CSF1R inhibitors
37:54
or integrating PI3K pathway inhibitors, the rationale
37:58
is that by hitting multiple targets or modulating
38:01
the tumor microenvironment, we can enhance the
38:03
efficacy of treatment, potentially overcome resistance,
38:06
and more effectively slow down disease progression,
38:09
ultimately aiming to reduce joint deterioration
38:11
and profoundly alleviate symptoms for longer.
38:13
That sounds promising. Are there challenges in
38:15
the research itself? There are. It's crucial
38:17
to acknowledge the research challenges that persist
38:19
in a rare disease like PVNS. Many existing studies,
38:23
particularly those investigating novel therapies,
38:25
often involve relatively small sample sizes simply
38:28
due to the low incidence, and sometimes they
38:30
have shorter follow -up durations. So we need
38:32
bigger, longer studies. Exactly. This highlights
38:35
a clear and pressing need for larger, multi -center
38:38
international trials with extended follow -up
38:41
periods. Such robust trials are essential to
38:45
rigorously validate current findings, to fully
38:48
unravel the complex genetic heterogeneity of
38:50
PVNS, and to comprehensively assess the long
38:53
-term efficacy and safety profiles of these newer,
38:56
targeted treatments in diverse patient populations.
38:59
But overall, there's hope. Definitely. The evolving
39:03
landscape of PVNS management offers significant
39:05
hope, particularly through these molecular breakthroughs,
39:08
for dramatically improving the long -term quality
39:10
of life and functional prognosis for our patients.
39:13
That vision for the future certainly offers a
39:16
great deal of hope. And given the really multifaceted
39:19
nature of this condition, from the delayed diagnosis
39:21
right through to complex treatment and long -term
39:23
management, it truly sounds like a condition
39:25
that benefits immensely from a properly joined
39:28
up approach. Absolutely. What, then, is the best
39:31
way for healthcare professionals across different
39:33
specialties to collaborate effectively for optimal
39:36
patient outcomes in PVNS, integrating all these
39:39
various facets of care we've discussed. You've
39:42
highlighted perhaps the most critical element
39:43
for achieving the best possible outcomes in PVNS,
39:46
a comprehensive interprofessional team approach.
39:49
This model goes beyond simply referring a patient
39:52
between specialists. It really integrates individual
39:55
patient goals, establishes realistic functional
39:58
outcomes, and ensures a truly coordinated care
40:01
pathway across multiple disciplines. Where does
40:03
that collaboration start? Diagnosis. Firstly,
40:07
yes, the diagnosis is optimally established through
40:09
the collaborative effort of the primary care
40:11
physician, who often first raises this suspicion
40:13
alongside radiologists, providing those critical
40:16
imaging insights and pathologists who give the
40:19
definitive microscopic confirmation from biopsy.
40:23
This upfront, coordinated collaboration ensures
40:26
the correct imaging studies are ordered and interpreted
40:28
accurately, leading to informed decisions about
40:31
the need for biopsy. It minimizes diagnostic
40:33
delays and ensures the patient gets onto the
40:35
correct treatment pathway as early as possible.
40:38
And once diagnosed. Once a diagnosis is confirmed,
40:42
multidisciplinary treatment planning becomes
40:44
paramount. The core care team typically includes
40:47
orthopedic surgeons, oncologists especially if
40:50
systemic therapy or radiation is being considered,
40:53
and clinical pharmacists. How should they work
40:55
together? These professionals should engage in
40:58
open, transparent discussions with the patient.
41:01
collaboratively establishing patient care goals,
41:04
and meticulously weighing the risks versus benefits
41:07
of surgical intervention versus systemic treatments.
41:10
For example, considering an oral medication like
41:13
pexadartinib for extensive diffuse disease, where
41:16
surgery is unlikely to succeed without prohibitive
41:18
morbidity, particularly in patients without major
41:21
hepatic comorbidities, that's a decision best
41:24
made collectively after a thorough case discussion
41:26
involving everyone. The pharmacist's role. The
41:28
pharmacy team plays a vital, often understated
41:31
role in medical treatment, meticulously verifying
41:34
ghosting, ensuring proper administration, diligently
41:37
checking for potential drug interactions or contraindications,
41:40
especially crucial with these novel molecular
41:42
therapies. And nursing and therapy support. Throughout
41:45
the entire diagnostic, treatment, and post -operative
41:48
phases, nursing staff with specialist training
41:50
in orthopedics and surgical care provide crucial
41:53
patient support, continuous evaluation, and tailored
41:57
counseling. If surgery is the chosen path, physical
42:00
therapists are absolutely indispensable for guiding
42:03
the rehabilitation process, helping patients
42:05
regain function, restore range of motion, and
42:08
rebuild muscle strength. And the effective management
42:11
of pain, which can be a common and persistent
42:13
symptom, should actively involve the pharmacist
42:16
to ensure effective and safe analgesic strategies
42:19
are implemented, considering the potential for
42:21
chronic pain. So it's a whole team effort. Absolutely.
42:25
By embracing this interprofessional team paradigm
42:27
where all these disciplines collaborate seamlessly,
42:30
we can ensure the most comprehensive and effective
42:32
patient outcomes, regardless of the specific
42:35
management pathway chosen. Anything else. And
42:37
I must underscore a crucial, often underutilized
42:40
element in this collaborative framework, patient
42:42
empowerment. Involving the patient more. Actively
42:45
increasing the patient's role in constructing
42:46
their collaborative treatment plan is not only
42:49
ethically sound, but is also empirically proven
42:52
to solidify patient compliance and significantly
42:55
improve long -term outcomes, not just in PVNS,
42:58
but across the entire spectrum of complex diseases.
43:02
Continued patient -physician collaboration right
43:04
from the initial diagnosis through treatment
43:06
and ongoing long -term management is unequivocally
43:09
advised for this challenging condition. That's
43:12
a fantastic point to end on the power of the
43:14
informed, engaged patient within that collaborative
43:17
team. What an extraordinary, albeit challenging
43:20
journey we've taken into the world of pigmented
43:22
villinodular synovitis today. We've certainly
43:26
had a truly comprehensive exploration, haven't
43:28
we? Covering everything from its rare incidence
43:30
and the complex pathophysiology driven by that
43:33
CSF1R pathway right through to its varied and
43:36
often deceiving clinical presentations and the
43:38
cutting edge multimodal treatments now available.
43:41
the profound importance of an integrated multidisciplinary
43:45
approach and genuine patient involvement truly
43:48
shines through as the cornerstone of effective
43:50
management. Ultimately, understanding PVNS isn't
43:54
just about dissecting its intricate biology,
43:56
is it? It's about appreciating the nuanced and
43:58
often protracted patient journey and that relentless
44:02
pursuit of better quality of life in the face
44:04
of a persistent locally aggressive disease. Well
44:07
said. If you found this deep dive insightful,
44:10
please do consider rating and sharing the deep
44:12
dive with a colleague who might also benefit
44:14
from these insights. Thank you so much for joining
44:17
us and sharing your invaluable expertise today.
44:19
It's been my pleasure. It's certainly a field
44:21
experiencing rapid advancements, particularly
44:23
with these molecular therapies, and staying abreast
44:26
of these developments truly offers significant
44:28
hope for revolutionizing long -term outcomes
44:30
for our patients.